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Her height was below -3. Growth hormone releasing factors (GRFs) have been isolated and characterized from pancreatic tumors in patients with acromegaly (Guillemin et al., 1982; Esch et al., 1982; Rivier et al., 1982) . Ling et al., (1984) isolated and characterized human hypothalamic GRF from human pituitary stalk median eminence extract and reported that its structure is identical to that of the 44-aminoacid GH releasing peptide isolated from the tumors. Thus we use the term hGRF to designate the human growth hormone releasing factor, either tumorous or hypothalamic. Using synthetic replicates of these human pancreatic GRFs, it has been demonstrated that the majority of patients with GH deficiency have GH responses to a single iv bolus and/or repeated administrations of the peptide by either im, sc or iv infusion (Borges et al., 1983; Grossman et al., 1983; Takano et al., 1984; Hizuka et al., 1984) . These patients are classified as hGRF deficient. When a patient is so diagnosed, hGRF administration may be a suitable replacement therapy.
However, only two cases with GRF deficiency were reported concerning the GRF treatment (Thorner et al., 1985) .
In the present study, we reported the effects of hGRF administration for three months in a patient with hGRF deficiency. Case Report
A 12-year-old girl was admitted to our hospital in December of 1982 for investigation of short stature. She was born on the 1st of November, 1970 at full term and weighed 3,080g.
She was fine until she went to kindergarten, when it was first noticed that her growth was retarded. However, as all other physical and mental development was normal, her parents dit not consult any doctors until she was 12 years old ( Fig. 1) . Her linear growth rate over the previous three years has been 2.2, 2.6 and 3.1cm per year, respectively, for a mean of 2.6 cm per year.
When she was admitted to the hospital her height and body weight were 125.1cm and 23 kg, which were below -3.5 SD and and visual examinations were normal. The pituitary functions were normal as shown in Table 1 . Tomography of the sella disclosed signs of calcified tumor in the suprasellar region. The brain CT scan disclosed an oval-shaped low density area in the midportion of the intrasellar region to suprasellar region with calcification of the wall and moderate dilatation of the lateral and third ventricles (Fig. 2) . ministration has an effect on growth stimulation in human subjects. It is too early to speculate on the advantages of hGRF over GH in the treatment of these children. The patterns of administration, subcutaneously twice a day or pulsatile infusion, seem more troublesome than hGH treatment. GH therapy is widely used in treating patients with GH deficiency by im injection of three to four times a week. More experience is required to evaluate of hGRF therapy with respect to dose, frequency of administration, and a strong, long acting analog of hGRF.
